Table 1 Demographic and clinical characteristics of 76 treated patients
Characteristics | All treated patients [N = 76] | Matching Score | P-values | ||||
|---|---|---|---|---|---|---|---|
≥ 60% [N = 27] | 1-59% [N = 27] | Unmatched [N = 22] | ≥ 60% vs. 1–59% | ≥ 60% vs. unmatched | 1–59% vs. unmatched | ||
Age, years* | |||||||
Median (range) | 63.0 (22.5-92.7) | 63.5 (36.4-82.6) | 62.3 (35.7-92.7) | 63.4 (22.5-86.4) | 0.82 | 0.92 | 0.85 |
≥ 63 | 38 (50%) | 14 (51.9%) | 13 (48.1%) | 11 (50.0%) | > 0.99 | > 0.99 | > 0.99 |
< 63 | 38 (50%) | 13 (48.1%) | 14 (51.9%) | 11 (50.0%) | -- | -- | -- |
Gender | |||||||
Women | 40 (52.6%) | 14 (51.9%) | 14 (51.9%) | 12 (54.5%) | > 0.99 | > 0.99 | > 0.99 |
Men | 36 (47.4%) | 13 (48.1%) | 13 (48.1%) | 10 (45.5%) | -- | -- | -- |
Ethnicity | |||||||
Caucasian | 45 (59.2%) | 15 (55.6%) | 19 (70.4%) | 11 (50.0%) | 0.40 | 0.78 | 0.24 |
Hispanic | 15 (19.7%) | 6 (22.2%) | 6 (22.2%) | 3 (13.6%) | > 0.99 | 0.49 | 0.49 |
Asian | 9 (11.8%) | 4 (14.8%) | 2 (7.4%) | 3 (13.6%) | 0.67 | > 0.99 | 0.65 |
African American | 3 (3.9%) | 2 (7.4%) | 0 (0.0%) | 1 (4.5%) | 0.49 | > 0.99 | 0.45 |
Others | 4 (5.3%) | 0 (0.0%) | 0 (0.0%) | 4 (18.2%) | -- | 0.04 | 0.04 |
Tumor type | |||||||
Gastrointestinal, non-colorectal | 12 (15.8%) | 4 (14.8%) | 3 (11.1%) | 5 (22.7%) | > 0.99 | 0.71 | 0.44 |
Carcinoma of unknown primary | 10 (13.2%) | 6 (22.2%) | 3 (11.1%) | 1 (4.5%) | 0.47 | 0.11 | 0.62 |
Hepatobiliary | 9 (11.8%) | 4 (14.8%) | 4 (14.8%) | 1 (4.5%) | > 0.99 | 0.36 | 0.36 |
Colorectal | 7 (9.2%) | 3 (11.1%) | 3 (11.1%) | 1 (4.5%) | > 0.99 | 0.62 | 0.62 |
Pancreatic | 7 (9.2%) | 1 (3.7%) | 2 (7.4%) | 4 (18.2%) | > 0.99 | 0.16 | 0.39 |
Head and neck | 5 (6.6%) | 2 (7.4%) | 2 (7.4%) | 1 (4.5%) | > 0.99 | > 0.99 | > 0.99 |
Appendiceal | 4 (5.3%) | 2 (7.4%) | 0 (0.0%) | 2 (9.1%) | 0.49 | > 0.99 | 0.20 |
Gynecologic | 4 (5.3%) | 0 (0.0%) | 2 (7.4%) | 2 (9.1%) | 0.49 | 0.20 | > 0.99 |
Breast | 3 (3.9%) | 1 (3.7%) | 2 (7.4%) | 0 (0.0%) | > 0.99 | > 0.99 | 0.50 |
Lung, non-small cell | 3 (3.9%) | 2 (7.4%) | 1 (3.7%) | 0 (0.0%) | > 0.99 | 0.50 | > 0.99 |
Genitourinary | 2 (2.6%) | 0 (0.0%) | 0 (0.0%) | 2 (9.1%) | -- | 0.20 | 0.20 |
Skin/melanoma | 2 (2.6%) | 1 (3.7%) | 1 (3.7%) | 0 (0.0%) | > 0.99 | > 0.99 | > 0.99 |
Others† | 8 (10.5%) | 1 (3.7%) | 4 (14.8%) | 3 (13.6%) | 0.35 | 0.31 | > 0.99 |
Number of genomic alterations per patient‡ | |||||||
Median (range) | 5 (0-15) | 5 (1-15) | 6 (0-11) | 4.5 (0-11) | 0.11 | 0.59 | 0.42 |
Number of drugs administered | |||||||
≥ 2 drugs | 62 (81.6%) | 25 (92.6%) | 20 (74.1%) | 17 (77.3%) | 0.14 | 0.22 | > 0.99 |
Single drug | 14 (18.4%) | 2 (7.4%) | 7 (25.9%) | 5 (22.7%) | -- | -- | -- |